Access Vascular, Inc.
Access Vascular is offering a suite of vascular access devices that use our novel, patented biomaterial featuring MIMIX™ technology which is designed to prevent the most common and costly complications in vascular access. Keep treatment moving forward with products that have demonstrated in clinical, in vivo and in vitro data to have a statistically significant reduction in complications compared to standard polyurethane catheters. Tackle most avoidable complications like occlusions and replacements - no coatings, fillers or surface modifications. Provide better patient experience - fewer device replacements means fewer unnecessary needle sticks and fewer delays in treatment. Potentially save up to 50% material costs over standard polyurethane catheters with reduced complications.
Transforming Vascular Access
Access Vascular was Founded to Transform Vascular Access.
Our company was founded to solve the significant yet unmet needs in vascular access. After shadowing physicians and learning about the challenge that thrombosis presents to vascular access, our founders set off to develop a new, groundbreaking biomaterial that is fundamentally different than the polyurethane used in conventional vascular catheters. Our foundationally unique, thrombus-evading catheters alleviate the clinical and economic burden from vascular access complications, so focus can remain on outcomes.
In 2018, we secured FDA clearance on our first product, a peripherally inserted central catheter (PICC) which was found to be effective in reducing thrombosis accumulation. In 2021, we received our second FDA clearance with the HydroMID a peripherally inserted midline catheter which has demonstrated 6x fewer complications then a standard polyurethane catheter.**
We are a privately held company based in Billerica, MA. Our headquarters consists of a 40,000 square foot facility that includes state-of-the-art laboratory and manufacturing spaces. We employ approximately 40 employees and our products are commercially available in the United States.
*Data on file at Access Vascular. Reduction of thrombus accumulation was evaluated using in vitro and in vivo models. Pre-clinical in vitro/in vivo evaluations do not necessarily predict clinical performance with respect to thrombus formation. **Bunch, J. (2022). A Retrospective Assessment of Peripheral Catheter Failures Focusing on Catheter Composition. J. Infus Nurs. Sept/Oct 2022
Access Vascular is committed to providing our customers with the highest quality intravascular products that meet or exceed expectations. Access Vascular commits to comply with the necessary requirements and regulations through the regular maintenance of an effective quality system and seeks to continuously improve its products.
Blood platelets react to the catheter material, forming blood clots that impede catheter flow and can lead to serious conditions like deep vein thrombosis and pulmonary embolism with DVT rates of up to 7%.1,2,3
Bacteria are introduced during catheter insertion or accumulate in thrombosed sections of the catheter wall, leading to bloodstream infections with 0.3% CLABSI per catheter day in clinical data.4, 5
Catheters can damage the vein wall during insertion, leading to swelling and pain with up to 35% incidence in peripheral catheters.6